“…The key role of the Na + /K + ‐ATPase in the CNS is underscored by mice with homozygous deletion of the genes coding for α2 ( ATP1A2 ) or α3 ( ATP1A3 ) dying at birth (Ikeda et al, ; Ikeda et al, ). Reduced Na + /K + ‐ATPase activity, possibly following cerebral ischemia, leads to excitotoxicity and cortical spreading depression (Haglund & Schwartzkroin, ; Major et al, ; Reiffurth, Alam, Zahedi‐Khorasani, Major, & Dreier, ), while altered expression of the Na + /K + ‐ATPase is observed in connection with diverse disease states (Grisar, Franck, & Delgado‐Escueta, ; Guillaume, Grisar, Delgado‐Escueta, Laschet, & Bureau‐Heeren, ; Lewis, Mutsuga, Schuette, & Van Buren, ; Scarrone et al, ). Mutations in the genes encoding the α2 or α3 isoforms are associated with severe neurological conditions, each of which strictly associates with mutations in one of the isoforms (Benarroch, ; Bottger, Doganli, & Lykke‐Hartmann, ; de Vries, Frants, Ferrari, & van den Maagdenberg, ): A range of mutations in ATP1A2 gives rise to familial hemiplegic migraine type 2 (FHM2) (de Fusco et al, ); a migraine associated with hemiparesis, seizures, and epilepsy (Bottger et al, ; Pietrobon, ), whereas mutations in ATP1A3 cause alternating hemiplegia of childhood (AHC), rapid‐onset dystonia parkinsonism (RDP), or early life epilepsy (Bottger et al, ; de Carvalho et al, ; Heinzen et al, ; Sweney, Newcomb, & Swoboda, ).…”